Stroke, Acute
Conditions
Keywords
Comprehensive stroke center, Ischemic stroke, Telestroke, Telemedicine, Secondary stroke prevention, COVID-19, SAR-Cov-2, pandemic
Brief summary
TELEstroke to CAre for STroke Patients at a Comprehensive Stroke Center (TELECAST-CSC) during the COVID-19 pandemic is a pre-post study evaluating guideline-based acute ischemic stroke care following the implementation of inpatient telestroke at a comprehensive stroke center during the COVID-19 global pandemic. TELECAST-CSC compares two cohorts: the in-person phase (December 1, 2019-March 15, 2020), when all inpatient stroke team care was delivered conventionally in-person and the telestroke phase (March 16, 2020-June 29, 2020) when all inpatient stroke team care was delivered exclusively via telestroke as part of our healthcare system's pandemic response. We studied the following primarily clinical endpoints: diagnostic stroke evaluation, secondary stroke prevention, health screening and evaluation, stroke education, mortality, and stroke recurrence and readmission rates.
Detailed description
The SARS-Cov-2 virus originated in Wuhan China in 2019 and rapidly became a global pandemic. Beyond the pandemic, stroke care is further impacted directly by COVID-19-induced systemic inflammatory response and coagulopathy which leads to increased risk of embolic stroke and intracranial hemorrhage. In the United States, the highest level of stroke care is provided to the most critically ill stroke patients at comprehensive stroke centers (CSCs). Many CSCs also utilize telestroke to deliver remote stroke care externally to partnering spoke hospitals without local stroke expertise in order to improve time-sensitive, emergent stroke interventions such as thrombolysis and thrombectomy. Conceptually, telestroke may also surmount pandemic-related barriers to stroke care delivery internally at CSCs and workflows incorporating telestroke have been adopted out of necessity. However, the efficacy of remote patient care via telestroke for stroke patients hospitalized at CSCs remains unclear. The aim of the TELECAST-CSC trial was to prospectively evaluate whether inpatient stroke specialist care provided via telestroke was equivalent to stroke care provided in-person during the COVID-19 pandemic. TELECAST-CSC compares two cohorts: the in-person phase (December 1, 2019-March 15, 2020), when all inpatient stroke team care was delivered conventionally in-person and the telestroke phase (March 16, 2020-June 29, 2020) when all inpatient stroke team care was delivered exclusively via telestroke as part of our healthcare system's pandemic response. We studied the following primarily clinical endpoints: diagnostic stroke evaluation, secondary stroke prevention, health screening and evaluation, stroke education, and stroke recurrence rates.
Interventions
OTHERTelestroke
In the telestroke cohort, acute ischemic stroke patients at a single comprehensive stroke center received their stroke care and management exclusively via telestroke.
Sponsors
University of Minnesota
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a pre-post interventional study following inpatient telestroke intervention for longitudinal treatment of acute ischemic stroke patients at a comprehensive stroke center. The pre-treatment group is the conventional in-personcohort. The post-treatment group is the telestroke cohort. The groups were non-randomly allocated. All acute ischemic stroke patients admitted during phase 1 were include in the in-person cohort and all acute ischemic stroke patients admitted during phase 2 were included in the telestroke cohort.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 and above * Patients with the primary diagnosis of ischemic stroke admitted to Fairview Southdale Hospitals * Evidence of stroke on MRI or CT or clinical diagnosis of acute ischemic stroke by the treating stroke service.
Exclusion criteria
* Patients less than 18 years old * Patients who leave the hospital against medical advice * Patients with goals of care that impact the stroke evaluation (i.e. comfort measures) * Patients who have an alternative diagnosis * Patients who opt out of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Guideline-Based Inpatient Stroke Care | Inpatient hospitalization defined as the patient's admission through their discharge date (on average < 1 week) | A 24-item global assessment of fundamental inpatient acute ischemic stroke care informed by 2019 AHA guidelines comprising 4 categories: Diagnostic evaluation: Neurologist evaluation, head CT or brain MRI, intracranial vascular imaging, cervical vascular imaging, LDL, HgA1C, troponin, EKG, telemetry, echocardiogram, and outpatient prolonged cardiac monitoring. Secondary prevention: antiplatelet, dual antiplatelet, anticoagulation, statin, anti-hypertensives, diabetes management, symptomatic carotid revascularization. . Health screening and evaluation: swallow evaluation, cognitive assessment, rehabilitation evaluation Stroke evaluation: tobacco cessation counseling, exercise/ lifestyle counseling, signs of stroke. Each subject will be assessed for completion of these metrics. When a metric is not applicable for a specific patient, it will not be included in the analysis of guideline-based inpatient stroke care (e.g. tobacco cessation in a non-smoker). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Stroke Recurrence | 30 and 90 days post-hospital discharge | The composite rate of recurrent TIA, ischemic stroke, or hemorrhagic stroke 30 and 90 days post-discharge |
| Readmission Rate | 30 and 90 days post-hospital discharge | Rates of 30 and 90 day readmission |
Other
| Measure | Time frame | Description |
|---|---|---|
| Health Screening & Evaluation | Inpatient hospitalization defined as the patient's admission through their discharge date (on average < 1 week) | The 3-item Health Screening & Evaluation assessment is one of four sub-components of the primary outcome. Health screening and evaluation: swallow evaluation, cognitive assessment, rehabilitation evaluation Each subject will be assessed for completion of these metrics. When a metric is not applicable for a specific patient, it will not be included in the analysis of guideline-based inpatient stroke care (e.g. tobacco cessation in a non-smoker). |
| Stroke Education | Inpatient hospitalization defined as the patient's admission through their discharge date (on average < 1 week) | The 3-item Stroke Education assessment is one of four sub-components of the primary outcome. Each subject will be assessed for completion of these metrics. Stroke evaluation: tobacco cessation counseling, exercise/ lifestyle counseling, signs of stroke. When a metric is not applicable for a specific patient, it will not be included in the analysis of guideline-based inpatient stroke care (e.g. tobacco cessation in a non-smoker). |
| Transfer Rate | Inpatient hospitalization defined as the patient's admission through their discharge date (on average < 1 week) | Transfer rate |
| Death | 30 and 90 days post-admission | Death rate 30 and 90 days post admission |
| Time to antiplatelet administration | From admission time until the first dose of antiplatelet administered in patients where antiplatelet treatment for secondary stroke prevention was indicated (assessed up to 1 week) | Time from admission to antiplatelet administration |
| Length of Stay | Inpatient hospitalization defined as the patient's admission through their discharge date (on average < 1 week) | Length of patient hospitalization |
| Diagnostic Stroke Evaluation | Inpatient hospitalization defined as the patient's admission through their discharge date (on average < 1 week) | The 11-item Diagnostic Stroke Evaluation assessment is one of four sub-components of the primary outcome. Diagnostic evaluation metrics: Neurologist evaluation, head CT or brain MRI, intracranial vascular imaging, cervical vascular imaging, LDL, HgA1C, troponin, EKG, telemetry, echocardiogram, and outpatient prolonged cardiac monitoring. Each subject will be assessed for completion of these metrics. When a metric is not applicable for a specific patient, it will not be included in the analysis of guideline-based inpatient stroke care (e.g. tobacco cessation in a non-smoker). |
| Secondary Stroke Prevention | Inpatient hospitalization defined as the patient's admission through their discharge date (on average < 1 week) | The 8-item Secondary Stroke Prevention assessment is one of four sub-components of the primary outcome. Secondary prevention: antiplatelet, dual antiplatelet, anticoagulation, statin, anti-hypertensives, diabetes management, symptomatic carotid revascularization. Each subject will be assessed for completion of these metrics. When a metric is not applicable for a specific patient, it will not be included in the analysis of guideline-based inpatient stroke care (e.g. tobacco cessation in a non-smoker). |
Countries
United States
Outcome results
None listed